Bio-Rad Laboratories (BIO-B) Change in Receivables (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of Change in Receivables data on file, last reported at $614.1 million in Q1 2026.

• Quarterly Change in Receivables fell 4.05% year-over-year to $614.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.6 billion (up 2.96% YoY) and the FY2025 annual result came in at $2.7 billion, up 4.05% from the prior year.
• Change in Receivables retreated to $614.1 million in Q1 2026 per BIO-B's latest filing, from $697.7 million in the prior quarter.
• Across five years, Change in Receivables topped out at $717.4 million in Q4 2022 and bottomed at $614.1 million in Q1 2026.
• The 5-year median for Change in Receivables is $655.5 million (2024), against an average of $659.2 million.
• The widest annual swing landed in 2022, when Change in Receivables decreased 10.72%; it then advanced 10.38% in 2025.
• Tracing BIO-B's Change in Receivables over 5 years: stood at $717.4 million in 2022, then slipped by 5.68% to $676.7 million in 2023, then declined by 6.59% to $632.1 million in 2024, then climbed by 10.38% to $697.7 million in 2025, then retreated by 11.98% to $614.1 million in 2026.
• Per Business Quant, the three latest BIO-B Change in Receivables figures stand at $614.1 million (Q1 2026), $697.7 million (Q4 2025), and $653.8 million (Q3 2025).

Peer Comparison